NRXP NRX PHARMACEUTICALS INC

NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th

NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th

WILMINGTON, Del., Sept. 03, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, today announced that Jonathan Javitt, M.D., M.P.H., Chairman and Chief Executive Officer of NRx Pharmaceuticals, will participate in a fireside chat at H.C. Wainwright’s 27th Annual Global Investment Conference on Monday, September 8, 2025, from 4:30 to 5:00 PM ET.

A webcast of the fireside chat will be available on the Events page of the Investors section of the Company’s website at . A replay of the webcast will be available two hours after the event and will be accessible for 30 days following the event.

Management will also be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the NRx Pharmaceuticals management team should contact their H.C. Wainwright representative or Brian Korb at astr Partners, .

About NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. () is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has recently filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression.

About HOPE Therapeutics, Inc.

HOPE Therapeutics, Inc. (), a subsidiary of NRx Pharmaceuticals, is a healthcare delivery company, which plans to build a best-in-class network of interventional psychiatry clinics to offer ketamine, transcranial magnetics stimulation (TMS), and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.

Notice Regarding Forward-Looking Statements

The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at . Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new

information, future events or otherwise.

For further information:

Matthew Duffy                                                                        

Co-CEO, Hope Therapeutics, Inc.                                          

Chief Business Officer, NRx Pharmaceuticals, Inc.              

                                                      
Brian Korb

Managing Partner, astr partners

(917) 653-5122



EN
03/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NRX PHARMACEUTICALS INC

 PRESS RELEASE

NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at...

NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th WILMINGTON, Del., Sept. 03, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, today announced that Jonathan Javitt, M.D., M.P.H., Chairman and Chief Executive Officer of NRx Pharmaceuticals, will participat...

 PRESS RELEASE

UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present ...

UPDATE -- NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller, Sponsored by Rockefeller Global Family Office NRx CEO presented plans for HOPE Therapeutics rollout in September 2025 and establishment of flagship location in Palm Beach, FL during symposium presentation with leadership from Rockefeller Capital and Matthew Rockefeller.Company has recently raised $8.8 million capital from experienced biotech investors with no warrants, repricing, or other variable rate features.HOPE clinics will combine treatment with neuroplast...

 PRESS RELEASE

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 202...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital NRx CEO presented plans for HOPE Therapeutics rollout in September 2025 and establishment of flagship location in Palm Beach, FL during symposium presentation with leadership from Rockefeller Capital and Matthew Rockefeller.Company has recently raised $8.8 million capital from experienced biotech investors with no warrants, repricing, or other variable rate features.HOPE clinics will combine treatment with neuroplastic drugs including ketamine, tran...

 PRESS RELEASE

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Poli...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Expanded Access Policy for NRX-100 (preservative-free ketamine) US Food and Drug Administration (FDA) has granted Fast Track designation for NRX-100 in the treatment of suicidal ideation in patients with depression, including bipolar depression.NRx Pharmaceuticals is making NRX-100 available on an expanded access basis upon physician request for patients with serious or life-threatening suicidal depression despite treatment with currently available therapy.Approximately 13 million adults seriously consider suicide each year, according to the...

 PRESS RELEASE

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Fi...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet medical need.Represents an approximately 10-fold expansion of the addressable market to 13 million Americans, compared to the original Fast Track Designation issued in 2017 for bipolar depression alone. The Designation letter contains a specific finding that NRX-100 addresses an “unm...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch